SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
化学名称: (Z)-2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-N-(3,5,6-trihydroxy-2-oxo-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexyl)but-2-enamide
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
微笑: C/C(O)=C(C#N)/C(N(C1=CC=C(C(F)(F)F)C=C1)CC(C(O)C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)C(O)CO)=O)=O
Teriflunomide Lactose Adduct 2 is chemically (Z)-2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-N-(3,5,6-trihydroxy-2-oxo-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexyl)but-2-enamide. Teriflunomide Lactose Adduct 2 is supplied with detailed characterization data compliant with regulatory guideline. Teriflunomide Lactose Adduct 2 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Teriflunomide.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution
Nukendra Prasad Nadella,Venkata Nadh Ratnakaram & N. Srinivasu
Journal of Liquid Chromatography & Related Technologies Volume 40, 2017 - Issue 10 Pages 517-527
Development of Validated Stability Indicating HPTLC Method for the Estimation of Teriflunomide in Bulk and Tablet Dosage Form
Karmankar, Snehal; Tajne, M.
Current Pharmaceutical Analysis, Volume 16, Number 7, 2020, pp. 814-822(9)